Advertisement

Topics

CymaBay Therapeutics to Present at Three Investor Conferences

19:00 EST 12 Nov 2017 | Globe Newswire

NEWARK, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will provide a corporate overview at the 29th Annual Piper Jaffray Healthcare Conference, the Evercore/ISI 2017 Biopharma Catalyst/Deep Dive Conference, and the Global Mizuho Investor Conference.

29th Annual Piper Jaffray Healthcare Conference
Date:Wednesday, November 29 
Time:12:00pm Eastern time 
Location:Lotte New York Palace Hotel 
Webcast:http://ir.cymabay.com/events 

 

Evercore/ISI 2017 Biopharma Catalyst/Deep Dive Conference
Date:Thursday, November 30 
Time:12:05pm Eastern Time 
Location:Boston Harbor Hotel 
Webcast:http://ir.cymabay.com/events 

 

Global Mizuho Investor Conference
Date:Tuesday, December 5
Time:One-on-One Format
Location:Lotte New York Palace Hotel


About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent and selective agonist of PPARδ, a nuclear receptor that regulates genes involved in bile acid/sterol, lipid and glucose metabolism and inflammation. Seladelpar is currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH. Arhalofenate is a potential urate-lowering anti-flare therapy that has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc.  CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.

For additional information about CymaBay visit www.cymabay.com.

Contact:              
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com

NEXT ARTICLE

More From BioPortfolio on "CymaBay Therapeutics to Present at Three Investor Conferences"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...